Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of PCOS patients. DESIGN: Controlled clinical study. SETTING: PCOS patients in a clinical research environment. PATIENTS: 20 overweight PCOS patients were enrolled after informed consent. INTERVENTIONS: All patients underwent hormonal evaluations and an oral glucose tollerance test (OGTT) before and after 12 weeks of therapy (Group A (n = 10): myo-inositol 2 gr. plus folic acid 200 mug every day; Group B (n = 10): folic acid 200 mug every day). Ultrasound examinations and Ferriman-Gallwey score were also performed. MAIN OUTCOME MEASURES: Plasma LH, FSH, PRL, E2, 17OHP, A, T, glucose, insulin, C peptide concentrations, BMI, HOMA index and glucose-to-insulin ratio. RESULTS: After 12 weeks of MYO administration plasma LH, PRL, T, insulin levels and LH/FSH resulted significantly reduced. Insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment. Menstrual cyclicity was restored in all amenorrheic and oligomenorrheic subjects. No changes occurred in the patients treated with folic acid. CONCLUSIONS: Myo-inositol administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ten used FA at doses ranging from 200 to 400 mcg daily (25, 27, 29, 31, 34, 37, 46-49).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [34]
In the citing paper
“Twenty studies compared MI alone at doses of 1 to 4 g daily either alone or in combination with FA 200 to 400 mcg daily (25-27, 30-34, 41, 42, 44, 46-55) against the comparators of metformin, FA alone, or placebo.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [34]
In the citing paper
“There were 8 studies (25, 27, 31, 34, 46-49) that compared MI + FA to FA alone.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [34]
In the citing paper
“There were no differences between groups for androgenicity outcomes, total testosterone (Fig. 4A, 3 studies), and androstenedione levels (Fig. 4B, 3 studies) (27, 31, 34).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [34]
In the citing paper
“The other 2 studies evaluated 2 g of MI daily with 200 mcg (34) or 400 mcg (27) of FA.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [34]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 1×
“In fact such altered insulin sensitivity or compensatory hyperinsulinemia has been frequently reported not only in overweight/obese PCOS [7] but also in lean/normal weight PCOS patients [5,6,8,9], thus supporting the hypothesis that insulin resistance might be independent from body weight.”
BackgroundKnochenhauer, E. S., Key, T. J., Kahsar-Miller, M., Waggoner, W., Boots, L. R., & Azziz, R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5090 · Cited by 1,516
Asunción, M., Calvo, R. M., San Millán, J. L., Sancho, J., Avila, S., & Escobar-Morreale, H. F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6682 · Cited by 1,318
NESTLER, J. E., POWERS, L. P., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., RITTMASTER, R. S., CLORE, J. N., & BLACKARD, W. G. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-83 · Cited by 815 · cited 1×
“Since hyperinsulinemia stimulates ovarian androgens production in PCOS patients [5,8,36] attention has been given to inositolphosphoglycan (IPG) mediators as post-receptor mediators or second messenger of insulin signaling [37,38].”
BackgroundThe homeostasis model in the San Antonio Heart Study.
Haffner, S. M., Miettinen, H., & Stern, M. P. (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1087 · Cited by 788 · cited 2×
“The glucose to insulin ratio [5,21] and the HOMA index [20], at baseline, were computed to estimate the sensitivity to insulin.”
MethodLegro, R. S., Finegood, D., & Dunaif, A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5054 · Cited by 673 · cited 1×
“The glucose to insulin ratio [5,21] and the HOMA index [20], at baseline, were computed to estimate the sensitivity to insulin.”
MethodDunaif, A., Xia, J., Book, C. B., Schenker, E., & Tang, Z. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118126 · Cited by 561 · cited 1×
“absence of diabetes [5–8,29], probably due to (especially in lean/normal-weight PCOS subjects) a genetic/familiar predisposition [29,30].”
BackgroundDunaif, A., Scott, D., Finegood, D., Quintana, B., & Whitcomb, R. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784087 · Cited by 524
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 16×
“Our present study has demonstrated that MYO is also effective on PCOS similarly to DCI.”
InfluentialEhrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
The Importance of Diagnosing the Polycystic Ovary Syndrome
Lobo, R. A., & Carmina, E. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-12-200006200-00010 · Cited by 309 · cited 1×
“Indeed PCOS-induced insulin resistance determines a higher risk for the development of type 2 diabetes, hypertension, dyslipidemia, all elements of the so called ‘‘syndrome X’’ or dysmetabolic syndrome [29,31].”
BackgroundInsulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
De Leo, V., la Marca, A., & Petraglia, F. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0015 · Cited by 286 · cited 4×
“Since hyperinsulinemia stimulates ovarian androgens production in PCOS patients [5,8,36] attention has been given to inositolphosphoglycan (IPG) mediators as post-receptor mediators or second messenger of insulin signaling [37,38].”
BackgroundInfluentialKolodziejczyk, B., Duleba, A. J., Spaczynski, R. Z., & Pawelczyk, L. (2000) · Fertility and Sterility · doi:10.1016/s0015-0282(00)00501-x · Cited by 255 · cited 1×
“good index of insulin sensitivity in women with PCOS [25,26].”
BackgroundLow Urinary chiro-Inositol Excretion in Non-Insulin-Dependent Diabetes Mellitus
Kennington, A. S., Hill, C. R., Craig, J., Bogardus, C., Raz, I., Ortmeyer, H. K., Hansen, B. C., Romero, G., & Larner, J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008093230603 · Cited by 218
Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome
Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P., Dillon, P., Gunn, R. D., Allan, G., & Nestler, J. E. (2002) · Endocrine Practice · doi:10.4158/ep.8.6.417 · Cited by 188 · cited 1×
“DCI administration has been demonstrated to reduce insulin resistance both in lean and obese PCOS patients improving ovarian function and decreasing hyperandrogenism [14,15].”
BackgroundMyo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction
Papaleo, E., Unfer, V., Baillargeon, J.-P., De Santis, L., Fusi, F., Brigante, C., Marelli, G., Cino, I., Redaelli, A., & Ferrari, A. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701672405 · Cited by 185 · cited 4×
“Papaleo E, Unfer V, Beillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A. Myoinositol in patients with polycystic ovary syndrome a novel method for ovulation induction.”
BackgroundResultInfluentialChiu, T. T. Y., Rogers, M. S., Law, E. L. K., Briton-Jones, C. M., Cheung, L. P., & Haines, C. J. (2002) · Human Reproduction · doi:10.1093/humrep/17.6.1591 · Cited by 182 · cited 5×
“Such a report sustained the hypothesis that MYO is required to enhance the developmental competence of maturing oocytes [18] probably through other concomitant effects.”
BackgroundResultInfluentialAsplin, I., Galasko, G., & Larner, J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.5924 · Cited by 168 · cited 1×
“specific D-chiro-inositol (DCI)-containing inositolphosphoglycan may underlie insulin resistance, similarly to type 2 diabetes [12,13].”
BackgroundHasegawa, I., Murakawa, H., Suzuki, M., Yamamoto, Y., Kurabayashi, T., & Tanaka, K. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00454-3 · Cited by 156
Second Messengers of Insulin Action
Saltiel, A. R. (1990) · Diabetes Care · doi:10.2337/diacare.13.3.244 · Cited by 148
Altered D-Chiro-Inositol Urinary Clearance in Women With Polycystic Ovary Syndrome
Baillargeon, J.-P., Diamanti-Kandarakis, E., Ostlund, R. E., Apridonidze, T., Iuorno, M. J., & Nestler, J. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1070 · Cited by 146 · cited 9×
“Indeed, in our study, MYO decreased insulin plasma levels, glucose-to-insulin ratio, HOMA index as well as other hormonal parameters such as LH, LH/FSH, testosterone and PRL, typically elevated in PCOS patients and determined the occurrence of normal menstrual cycles in all patients under study similarly to DCI [14,16…”
BackgroundResultInfluentialGenazzani, A. D., Battaglia, C., Malavasi, B., Strucchi, C., Tortolani, F., & Gamba, O. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.05.020 · Cited by 141 · cited 6×
“The glucose to insulin ratio [5,21] and the HOMA index [20], at baseline, were computed to estimate the sensitivity to insulin.”
BackgroundMethodSelf-citationInsulin Sensitizers for Polycystic Ovary Syndrome
BAILLARGEON, J.-P., IUORNO, M. J., & NESTLER, J. E. (2003) · Clinical Obstetrics and Gynecology · doi:10.1097/00003081-200306000-00011 · Cited by 132
Ciampelli, M., Fulghesu, A. M., Cucinelli, F., Pavone, V., Ronsisvalle, E., Guido, M., Caruso, A., & Lanzone, A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90028-8 · Cited by 131 · cited 1×
“In fact such altered insulin sensitivity or compensatory hyperinsulinemia has been frequently reported not only in overweight/obese PCOS [7] but also in lean/normal weight PCOS patients [5,6,8,9], thus supporting the hypothesis that insulin resistance might be independent from body weight.”
BackgroundGerli, S., Mignosa, M., & Renzo, G. C. D. (2003) · PubMed · Cited by 125
Baker, L. W., Piddington, R., Goldman, A., Egler, J. M., & Moehring, J. (1990) · Diabetologia · doi:10.1007/bf00400202 · Cited by 112 · cited 2×
“Our data support the hypothesis of a primary role of IPG as second messenger of insulin signal and are in agreement with previous studies [14,16,17,18,19,25] and demonstrate that MYO administration significantly affect the hormonal milieu in PCOS patients.”
BackgroundResultEffects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes
Chiu, T. T. Y. (2003) · Human Reproduction · doi:10.1093/humrep/deg113 · Cited by 111 · cited 3×
“Our data support the hypothesis of a primary role of IPG as second messenger of insulin signal and are in agreement with previous studies [14,16,17,18,19,25] and demonstrate that MYO administration significantly affect the hormonal milieu in PCOS patients.”
BackgroundResultLarner, J. (1988) · Diabetes · doi:10.2337/diab.37.3.262 · Cited by 97 · cited 1×
“Since hyperinsulinemia stimulates ovarian androgens production in PCOS patients [5,8,36] attention has been given to inositolphosphoglycan (IPG) mediators as post-receptor mediators or second messenger of insulin signaling [37,38].”
BackgroundTaylor, A. E. (1998) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70045-1 · Cited by 95
Insulin Mediators and the Mechanism of Insulin Action
Romero, G. G., & Larner, J. (1993) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60932-1 · Cited by 90 · cited 1×
“However recent studies suggest that some abnormal action of insulin might be dependent from inositolphosphoglycan (IPG) mediators of insulin action [10,11] and suggest that a deficiency in a”
BackgroundMitwally, M. F. M., Kuscu, N. K., & Yalcinkaya, T. M. (1999) · Human Reproduction · doi:10.1093/humrep/14.11.2700 · Cited by 89
Genazzani, A. D., Lanzoni, C., Ricchieri, F., Baraldi, E., Casarosa, E., & Jasonni, V. M. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701214398 · Cited by 62 · cited 4×
“Indeed, in our study, MYO decreased insulin plasma levels, glucose-to-insulin ratio, HOMA index as well as other hormonal parameters such as LH, LH/FSH, testosterone and PRL, typically elevated in PCOS patients and determined the occurrence of normal menstrual cycles in all patients under study similarly to DCI [14,16…”
BackgroundSelf-citationEvidence of luteinizing hormone secretion in hypothalamic amenorrhea associated with weight loss
Genazzani, A. D., Petraglia, F., Fabbri, G., Monzani, A., Montanini, V., & Genazzani, A. R. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)53693-0 · Cited by 61 · cited 2×
“Plasma LH and FSH concentrations were determined using a previously described immunofluorimetric assay (IFMA) [22,23].”
BackgroundMethodSelf-citationGenazzani, A. D., Petraglia, F., Benatti, R., Montanini, V., ALGERI, I., Volpe, A., & Genazzani, A. R. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-6-1220 · Cited by 59 · cited 1×
“Plasma LH and FSH concentrations were determined using a previously described immunofluorimetric assay (IFMA) [22,23].”
MethodSelf-citationGenazzani, A. D., Petraglia, F., Pianazzi, F., Volpogni, C., & Genazzani, A. R. (1993) · Gynecological Endocrinology · doi:10.3109/09513599309152477 · Cited by 35 · cited 1×
“Plasma E2, 17-OHP, A, cortisol and T were determined by radioimmunoassay (Radim, Pomezia, Rome, Italy) as previously described [24].”
MethodSelf-citationInsulin resistance and the polycystic ovary syndrome: recent advances
Nestler, J. E. (2000) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200012000-00009 · Cited by 25 · cited 2×
“absence of diabetes [5–8,29], probably due to (especially in lean/normal-weight PCOS subjects) a genetic/familiar predisposition [29,30].”
Background
Research works printed but not linked: 8
- Zawadsky J K, 1992, Current Issues in Endocrinology and Metabolism: Polycystic Ovary Syndrome, 377
- Gerli S, 2003, Eur Rev Med Pharmacol Sci, 7, 151
- Legro R S, 1998, J Clin Endocrinol Metab, 83, 2694
- Asuncion M, 2000, J Clin Endocrinol Metab, 85, 2434
- Knochenhauser E S, 1998, J Clin Endocrinol Metab, 83, 3078
- Ehrmann D A, 1997, J Clin Endocrinol Metab, 82, 2108
- Dunaif A, 1996, J Clin Endocrinol Metab, 81, 3299
- 10.2337/diacare.13.3.244 · DOI · Paper page
Cited by
Potential role and therapeutic interests of myo-inositol in metabolic diseases
Croze, M. L., & Soulage, C. O. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.011 · Cited by 578
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201
“metformin [36] and in four of these trials [20,22,35,36] the dosage of 4 g of MYO was used; in one trial [34] 2 g of MYO were used.”
BackgroundMethodInfluentialMyo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017) · Endocrine Connections · doi:10.1530/ec-17-0243 · Cited by 188
“Studies were conducted in Italy (46, 47, 48, 49, 50, 51, 52), Georgia (53) and Turkey (54) and were published between 2007 and 2016.”
Antioxidants for female subfertility
Showell, M. G., Brown, J., Clarke, J., & Hart, R. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007807.pub2 · Cited by 184
Yang, J., & Chen, C. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0342 · Cited by 169
Metadata
- Authors
- Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Corresponding author
- Genazzani, Alessandro D.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 24
- Issue
- 3
- Pages
- 139-144
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2034664451
- Cited by
- 221
- References
- 37
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 12 · 2023: 17 · 2022: 10 · 2021: 16 · 2020: 24 · 2019: 10 · 2018: 14 · 2017: 20 · 2016: 23 · 2015: 11 · 2014: 15 · 2013: 13 · 2012: 2
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- Gynecological Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- myo-inositol, polycystic ovary syndrome, hyperinsulinemia, insulin sensitivity, folic acid, LH/FSH ratio, luteinizing hormone, menstrual cyclicity, HOMA index, glucose-to-insulin ratio, reproductive axis, overweight women
- MeSH terms
- Blood Glucose, Body Weight, Estradiol, Female, Folic Acid, Follicle Stimulating Hormone, Glucose Tolerance Test, Hormones, Humans, Hyperinsulinism, Inositol, Insulin, Luteinizing Hormone, Polycystic Ovary Syndrome, Prolactin, Testosterone, Ultrasonography, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.